Korea Gains Speed In Race For NASH Therapies
Major Deals And Growing Pipeline
Executive Summary
NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.
You may also be interested in...
ADCs, Oncology Move To Fore In Korean Biopharma Alliances
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio
Yuhan reaches $870m NASH licensing-out deal with Boehringer, touting its competitiveness in the space after earlier alliance with Gilead. The collaboration for first-in-class GLP-1/FGF21 dual agonist is poised to beef up German firm's R&D expertise in cardiometabolic disease.